CLINICAL & PIPELINE·Phase 3 Completion
Agios Pharmaceuticals Halts Tebapivat Development for Sickle Cell Disease Amidst Mid-Stage Trial Disappointment
Agios Pharmaceuticals has halted mid-stage development of tebapivat for sickle cell disease due to insufficient differentiation, impacting its competitive position against Novo Nordisk. This setback elevates the commercial importance of Agios's mitapivat, which holds US FDA Priority Review for sickle cell with an approval decision expected by November 1. Procurement and supply chain leaders must monitor the volatile sickle cell market.
90-Day Activity